4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Risk and Volatility
4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
Profitability
This table compares 4D Molecular Therapeutics and Sangamo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 4D Molecular Therapeutics | -194.74% | -41.33% | -35.90% |
| Sangamo Therapeutics | -310.81% | -2,662.06% | -132.12% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 4D Molecular Therapeutics | $85.21 million | 7.92 | -$140.11 million | ($2.63) | -4.64 |
| Sangamo Therapeutics | $39.55 million | 0.78 | -$122.93 million | ($0.38) | -0.19 |
Sangamo Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for 4D Molecular Therapeutics and Sangamo Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 4D Molecular Therapeutics | 1 | 1 | 10 | 0 | 2.75 |
| Sangamo Therapeutics | 2 | 1 | 1 | 0 | 1.75 |
4D Molecular Therapeutics currently has a consensus price target of $28.90, suggesting a potential upside of 136.59%. Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics’ higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than 4D Molecular Therapeutics.
Insider & Institutional Ownership
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
4D Molecular Therapeutics beats Sangamo Therapeutics on 10 of the 14 factors compared between the two stocks.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
